The QualityStocks Daily Tuesday, July 30th, 2019

Today's Top 3 Investment Newsletters

QualityStocks (SENY) +78.26%

StockMarketWatch (LXU) +29.22%

StreetInsider (HTBX) +26.66%

The QualityStocks Daily Stock List

Syncora Holdings Ltd. (SYCRF)

Zacks, ValueWalk, Wallmine, The Learning Investor, Insider Financial, Last10k, Wallet Investor, GuruFocus, InvestorsHub, Morningstar, Equities, Stockhouse, Equity Clock, Capital Cube, Market Screener, and GlobeNewswire reported previously on Syncora Holdings Ltd. (SYCRF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Syncora Holdings Ltd. is a Bermuda holding company headquartered in Hamilton, Bermuda. Its wholly-owned subsidiary Syncora Guarantee, Inc. provides financial guarantee insurance and reinsurance and credit enhancement for the obligations of debt issuers around the world. The Company formerly went by the name Security Capital Assurance Ltd. Established in 2006, Syncora Holdings’ shares trade on the OTC Markets.

Syncora Guarantee, Inc. is the New York-based subsidiary. It provides primary financial guarantee insurance to debt issuers globally. Syncora guarantees U.S. municipal bonds; asset-backed securities; debt backed by utilities and selected infrastructure projects; specialized risks, including future flow securitizations and bank deposit insurance; and collateralized debt obligations. Furthermore, the Company invests in private debt and equity securities.

Syncora Holdings announced this past March that its Board of Directors began a formal review process to explore and evaluate strategic alternatives for the Company centered on optimizing shareholder value and returning capital to shareholders. These alternatives include, among other things, a sale of part or all of Syncora Holdings or its wholly-owned, New York financial guarantee insurance subsidiary, Syncora Guarantee, Inc. The Board is being advised by Moelis & Company LLC, its financial advisor, Debevoise & Plimpton LLP, its U.S. legal advisor, and Appleby, its Bermuda legal advisor.

Last week, Syncora Holdings announced that it plans to host a conference call at 8:30 a.m. on August 15, 2019. This conference call to discuss its GAAP financial results for the six months ended June 30, 2019. A press release detailing this period will be issued after market close on August 14, 2019. At the same time, the Company's consolidated GAAP financial statements for the six months ended June 30, 2019, and certain additional information relating to the financial results, will be made available on Syncora Holding’s website (www.syncora.com). The call will be webcast through the Investor Events page of the Investor Relations section of Syncora’s website.

Syncora Holdings Ltd. (SYCRF), closed Tuesday's trading session at $5.22, up 0.384615%, on 10,190 volume with 31 trades. The average volume for the last 3 months is 112,680 and the stock's 52-week low/high is $2.72000002/$5.30000019.

chart

Humanigen, Inc. (HGEN)

NetworkNewsWire, TipRanks, Proactive Investors, GlobeNewswire, InvestorsHub, Insider Financial, Morningstar, Stockhouse, StreetWise Reports, 4-Traders, Trading View, Investors Hangout, Whale Wisdom, Street Insider, Equity Clock, Barchart, Proactive Investors, and Stockopedia reported previously on Humanigen, Inc. (HGEN), and today we are highlighting Company, here at the QualityStocks Daily Newsletter.

Humanigen, Inc. is developing its Humaneered® proprietary monoclonal antibodies to address critical unmet needs in today's most advanced cancer therapies. A biopharmaceutical Company, it is developing its portfolio of Humaneered® monoclonal antibodies centered on CAR-T optimization and immuno-oncology. Humaneering is a patented proprietary technology for converting suboptimal antibodies into human antibodies suitable for chronic therapies, in part, because of low immunogenicity. The Company previously went by the name KaloBios Pharmaceuticals, Inc. It changed its name to Humanigen, Inc. in August of 2017. Humanigen is based in Burlingame, California.

Derived from the Company’s Humaneered® platform, lenzilumab and ifabotuzumab, and HGEN005 are monoclonal antibodies with first-in-class mechanisms. Lenzilumab targets GM-CSF. It is in development as a potential biologic therapy to make CAR-T therapy safer and more effective, as well as a potential treatment for hematologic cancers.

Ifabotuzumab targets the Eph type-A receptor 3 (EphA3). It is being explored as a potential treatment for glioblastoma multiforme (GBM) and a range of solid tumors, as an optimized naked antibody and as part of an antibody-drug conjugate, and also as a backbone for a novel CAR-T construct, and a bispecific antibody platform.

HGEN005 selectively targets the eosinophil receptor EMR1. It is being explored as a potential treatment for a range of eosinophilic diseases including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct.

In early July, Humanigen announced that it entered into an exclusive worldwide license with the Mayo Clinic to certain technologies used to create CAR-T cells lacking GM-CSF expression through different gene-editing tools including CRISPR-Cas9 (GM-CSF knock-out). The license covers diverse patent applications and know-how developed by Mayo in collaboration with Humanigen. These licensed technologies complement and broaden the Company’s leadership position in the GM-CSF neutralization space and expands its discovery platform aimed at improving CAR-T to include gene-edited CAR-T cells.

Last week, Humanigen announced that it secured an exclusive worldwide license agreement from the University of Zurich (UZH) for technology used to prevent GvHD through GM-CSF neutralization. The technology was recently featured in a publication in Science Translational Medicine entitled “Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells”1. The Humanigen license encompasses varied patent applications filed by UZH that complement and broaden Humanigen’s leadership position in the application of GM-CSF and expand its development platform to include improving allogeneic HSCT.

Humanigen, Inc. (HGEN), closed Tuesday's trading session at $0.85, even for the day, on 3,704 volume. The average volume for the last 3 months is 3,704 and the stock's 52-week low/high is $0.430000007/$1.54400002.

chart

Magellan Gold Corporation (MAGE)

The OTC Reporter, Mining Stock Valuator, Mining Clips, Mining Capital, Market Screener, Street Insider, Equities, Investors Hangout, Stockwatch, Stockhouse, Proactive Investors, YCharts, Wallet Investor, and InvestorsHub reported earlier on Magellan Gold Corporation (MAGE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Magellan Gold Corporation (MAGE) intends to establish itself as a major player in the precious metals mining field. The Company is an exploration stage enterprise and its chief business is the acquisition, exploration, and if warranted, development of mineral resources. Magellan controls three projects consisting of the SDA Mill, Mexico; the El Dorado Gold-Silver Project near the SDA Mill; and the Silver District Property, Arizona. Magellan Gold has its head office in Albuquerque, New Mexico.

Magellan Gold intends to build up production through the SDA Mill and increase cash flow. Initial production from the El Dorado Gold-Silver Project is planned for 2019, with the ore to be trucked to the SDA Mill for treatment. Other precious metals properties within trucking distance of the SDA Mill have been identified for acquisition. Additionally, Magellan will take advantage of opportunities to treat ore on a toll basis for third-party suppliers.

The SDA Processing Plant is a permitted, fully operational flotation mill with gold-silver leach circuit located in Nayarit State, Mexico. The SDA Processing Plant (SDA Mill) is 150 kilometers southeast of the City of Mazatlan near the town of Acaponeta, Nayarit. Magellan Gold purchased the SDA Mill and associated assets, licenses and agreements in November of 2017 for a price of $1.5 million.

The El Dorado Gold-Silver Project is planned to be developed as an underground mine to supply feed to the SDA Mill. The El Dorado Gold-Silver Project is near the village of Las Minitas, State of Nayarit, 50 kilometers south of the SDA Processing Plant. The El Dorado Mining Concession consists of a 50-hectare concession valid until March 2030. Magellan Gold holds the concession under an option to purchase.

The Silver District Project is an advanced-stage exploration project in southwest Arizona. The Company’s Silver District Project in La Paz County holds promising potential for expansion of a historic 16 million ounce silver resource, and development of a silver mine with by-products fluorspar, barite and lead-zinc.

The property consists of over 2,000 acres of patented and unpatented mining claims and an Arizona state exploration permit. It encompasses all of the important historic mines and prospects in the Silver District.

Last week, Magellan Gold announced the immediate appointment of Mr. Frank A. Pastorino as Chief Operating Officer (COO), further strengthening Magellan’s senior management team. The Company announced Mr. David Drips as President & Chief Executive Officer (CEO) on June 19, 2019.

Mr. Pastorino has over 15 years of experience in the mining and metals industry including ten years outside of North America. He is experienced in the organizational, financial, and technical aspects of start-up and rehabilitation operations in challenging and dynamic environments for both public and private organizations.

Magellan Gold Corporation (MAGE), closed Tuesday's trading session at $2.00, even for the day, on 650 volume. The average volume for the last 3 months is 699 and the stock's 52-week low/high is $0.800000011/$3.79999995.

chart

MobileSmith, Inc. (MOST)

Zacks, Market Exclusive, YCharts, MarketWatch, Simply Wall St, Market Screener, Stockhouse, Wallet Investor, Last10k, InvestorsHub, Wallmine, GuruFocus, Capital Cube, Stockopedia, Stockwatch, Proactive Investors, Trading View, 4-Traders, and Dividend Investor reported previously on MobileSmith, Inc. (MOST), and we also report on the Company, here at the QualityStocks Daily Newsletter.

MobileSmith, Inc. is a leader in the digital health and mobile development sector. The Company provides operational improvement member-facing mobile application (app) services to the healthcare industry in the United States. It helps its clients improve health outcomes, patient satisfaction and grow profit margins using its toolbox of proven mobile app technologies. The Company is changing healthcare one app at a time through targeting the evident inefficiencies in the U.S. healthcare delivery model. MobileSmith is based in Raleigh, North Carolina.

The Company is helping its clients meet their healthcare consumers where they are, on their mobile devices, to expand the reach of providers to modify behavior with apps that remind, educate, track, and also engage the patients that use them. More than 60 healthcare systems and organizations are partnering with MobileSmith Health to deliver a new healthcare experience and embrace the impact of technology as an agent of change.

MobileSmith is focusing on select patient segments that struggle with areas such as medication adherence, discharge instruction compliance, and health literacy, and provide new innovative digital patient experiences including indoor navigation and clinic “check-ins”, which directly improve critical patient satisfaction.

Through the use of MobileSmith Health Blueprints, hospitals and other healthcare organizations can customize their apps based on specific feature sets, workflow, branding, protocol, procedure and service line. This is while launching in as little as 90 days. Last week, MobileSmith Health announced the collaboration with Hardtner Medical Center on the release of a patient portal app - Hardtner Access. The Louisiana-based medical center turned to MobileSmith Health to develop its first app with the aim of increasing patient portal usage among its rural area patient population.

The Hardtner Access App was built using MobileSmith Health’s signature Blueprints. It provides users with vital information, including a directory of physicians and departments along with lists of the medical center’s services. Additionally, users can access their own information through the patient portal and also refill prescriptions, find the nearest location using their phones’ built-in GPS and access information to help answer health questions that users may have.

MobileSmith, Inc. (MOST), closed Tuesday's trading session at $1.88, even for the day, on 7,500 volume. The average volume for the last 3 months is 795 and the stock's 52-week low/high is $0.75/$2.50999999.

chart

Predictive Technology Group, Inc. (PRED)

NetworkNewsWire, Zacks, OTC Markets, StreetWise Reports, pm360, Equity Clock, Wallet Investor, Investors Hangout, Business Insider, 4-Traders, Insider Tracking, Dividend Investor, Market Screener, Proactive Investors, InvestorsHub, Insider Financial, Simply Wall St, Stockhouse, Wallmine, and Infront Analytics reported beforehand on Predictive Technology Group, Inc. (PRED), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Predictive Technology Group, Inc. is a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments. The Company’s goal is to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics via its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. Predictive Technology Group has its corporate office in Salt Lake City, Utah.

The Company’s subsidiaries focus on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. These subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.

Further to Predictive Technology’s efforts to advance regenerative medicine, it is dedicated to assisting women in overcoming the devastating consequences of endometriosis through appropriate early-stage diagnosis and subsequent treatment. Predictive Biotech, Inc., a Salt Lake City life sciences company, is a leader in human cell and tissue products for use in regenerative medicine. A growing national network of clinics, health systems, researchers and physicians take advantage of Predictive’s four main placental-derived and Wharton’s jelly umbilical cord-derived products.

Predictive Laboratories focuses on clinical and discovery work for human infertility and genetic conditions affecting women and children. This includes endometriosis, scoliosis and degenerative disc disease. Testing is performed using state-of-the-art instrumentation at its CAP and CLIA accredited facility.

In June, Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, announced that data from a study of the genes underlying endometriosis may lead to new pathophysiology insights, improved diagnostics, as well as novel treatment approaches. The study data was discussed in an oral presentation by Kenneth Ward, M.D. at the 2019 European Society of Human Reproduction and Embryology (ESHRE) annual meeting in Vienna, Austria.

This month, Predictive Technology Group announced the continuation of consecutive quarter Revenue growth for the fiscal 2019 Q4 ended June 30, 2019.

Mr. Bradley Robinson, Chief Executive Officer of Predictive Technology Group, said, “We are proud of our revenue growth, fundamentals and business momentum. We continue to make excellent progress with our strategy to increase sales from our human cell and tissue products, while preparing for the full commercial launch in the coming quarters of our genetic-based endometriosis and fertility diagnostic/prognostic tests.”

Predictive Technology Group, Inc. (PRED), closed Tuesday's trading session at $1.83, up 1.6667%, on 483,542 volume with 592 trades. The average volume for the last 3 months is 581,833 and the stock's 52-week low/high is $0.76999998/$6.90999984.

chart

Tel-Instrument Electronics Corp. (TIKK)

Stock Twits, Zacks, Simply Wall St, Infront Analytics, Investors Hangout, Trading View, Business Wire, Whale Wisdom, MarketBeat, and Market Screener reported previously on Tel-Instrument Electronics Corp. (TIKK), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Tel-Instrument Electronics Corp. is the industry leader in developing and producing field-tested, robust avionic flight line and bench test sets for demanding military and commercial customers. The Company designs, manufactures, and sells avionics test and measurement solutions. These are for the commercial air transport, general aviation, and government/military aerospace and defense markets in the U.S. and around the world. Established in 1947, Tel-Instrument Electronics is headquartered in East Rutherford, New Jersey.

Tel-Instrument Electronics operates in two segments, Avionics Government and Avionics Commercial. It operates in the Aerospace & Defense industry in the Industrials sector. Tel-Instrument Electronics is ISO-9001:2015 quality certified. The Company is compliant to ESD standard ANSI/ESD S20.20 and its products have received CE certification for sales into Europe.

Tel-Instrument’s products have led the avionics support equipment industry to higher levels of integration through combining more test functions into a single unit. This lessens customer acquisition, training, and life-cycle support costs. The Company provides instruments to test, measure, calibrate, and repair a spectrum of airborne navigation and communication equipment. In addition, its products include TS-4530A, an identification friend or foe test set; T-47/M5, a dual crypto test set; and AN/ARM-206, an intermediate level TACAN test set.

Tel-Instrument Electronics also offers AN/USM-708 and AN/USM-719, which are communications/navigation radio frequency avionics flight line testers; TR-220, a test set that provides test capability for traffic and collision avoidance systems (TCAS), distance measuring equipment, and transponders; TR-36, a commercial navigation and communication test set that provides ramp testing; and TR-420, a ramp test set to test the operation of transponders and interrogators.

Furthermore, the Company provides multifunction ramp test sets under the T-47NC, T-47NH, and T-47G names; TR-100AF, a rugged ramp test used to verify airborne TACAN equipment; and AN/APM-480A, a transponder, interrogator, and TCAS test set.

This month, Tel-Instrument Electronics reported Net Income of $203,038 on Revenues of $12,116,050 million for the fiscal year ended March 31, 2019. Annual Revenues increased 21 percent to $12.1 million with $8.1 million recorded in the second half of the fiscal year. Gross Margins improved to 45 percent in comparison to 31 percent in the year ago period because of manufacturing efficiencies and cost controls. The Company had Net Income of $203k versus a $4.4 million Net Loss last year that included Aeroflex legal damages.

Tel-Instrument Electronics Corp. (TIKK), closed Tuesday's trading session at $2.41, up 7.1111%, on 538 volume with 7 trades. The average volume for the last 3 months is 2,277 and the stock's 52-week low/high is $2.25/$6.00.

chart

Westleaf, Inc. (WSLFF)

Stock Target Advisor, Pinnacle Digest, Wallmine, Trading View, Stockwatch, Investor Ideas, Insider Financial, MarketWatch, Stockhouse, YCharts, Midas Letter, InvestorsHub, Technical420, Business Insider, Morningstar, and Investors Hangout reported earlier on Westleaf, Inc. (WSLFF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Westleaf, Inc. engages in the cultivation, extraction, distribution, and sale of cannabis and cannabis related products. The Company is a vertically integrated cannabis business. It has assets owned and under development across cultivation, extraction, processing, manufacturing, and wholly-owned retail. OTCQB-listed, Westleaf is based in Calgary, Alberta.

Westleaf is developing a national presence of retail stores called Prairie Records. This is a brand that celebrates the instinctual tie between music and recreational cannabis. Prairie Records provides access to the country’s best cannabis. It is a reinvention of the cannabis purchasing experience in a high design, sophisticated retail space, reflecting that of a modern record store.

The Company’s brands also include Loon Cannabis and Westleaf Cannabis. Loon Cannabis is a health and wellness cannabis line. The design of it is to help customers live their optimal lives, so they can thrive and enjoy life with clarity and peace of mind. Loon Cannabis has a variety of calming strains and innovative products.

Westleaf Cannabis created a signature brand of medicinal cannabis products for customers looking to treat symptoms of illness and other conditions. The design of these products is to help customers reduce pain or to moderate side effects from continuing health conditions.

Westleaf has its e-commerce site for sales across the entire Province of Saskatchewan. The retail site, at www.prairierecords.ca, provides consumers in Saskatchewan convenient online access to a broad array of products via the unique Prairie Records retail concept, which combines music and cannabis in an engaging online experience. Last week, Westleaf announced that its subsidiary, Westleaf Labs LP, entered into a white labeling agreement with Delta 9 to supply roughly $4 million of cannabis derivative products from its large-scale extraction and manufacturing facility in Calgary, Alberta, known as The Plant. Under the terms of the agreement, the contract will commence on October 1, 2019, subject to receipt of final license approval from Health Canada. It will carry an initial term of one year, whereby Delta 9 will be required to purchase a minimum of approximately $4 million of different white labelled derivative products (such products are expected to include a mix of vape pens, gel caps, tincture oil, and edibles) with an option to increase the amount up to $16 million annually.

Westleaf, Inc. (WSLFF), closed Tuesday's trading session at $0.3385, off by 1.3982%, on 18,513 volume with 19 trades. The average volume for the last 3 months is 86,660 and the stock's 52-week low/high is $0.298999994/$5.00.

chart

Nu-Med Plus, Inc. (NUMD)

Stockhouse, Wallet Investor, OTC Markets, Marketwired, Investing News, Street Insider, The StreetWise Reports, MarketWatch, The Street, Venture Line, Stockopedia, Business Insider, Morningstar, GuruFocus, Capital Cube, last10k, TradingView, Wallmine, and Stockwatch reported earlier on Nu-Med Plus, Inc. (NUMD), nd today we report on the Company, here at the QualityStocks Daily Newsletter.

Nu-Med Plus, Inc. investigates and develops applications of Nitric Oxide technologies in the medical field. The OTCQB-listed Company formed to explore medical applications of newly developed technologies. Its strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. A medical device business, the Company is headquartered in Salt Lake City, Utah.

Inhaled Nitric Oxide (INO) is a medically essential gas. It is currently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), COPD and other pulmonary problems. Nu-Med Plus has the capability to deliver high purity Inhaled Nitric Oxide (INO) to the patient at point of use. INO may have future applications for an assortment of other diseases and medical complications that are now being investigated.

Nu-Med’s markets include neonatal complications, COPD, Tuberculosis, Malaria, and ARDS (a severe lung syndrome with no known cure). The Company’s team has developed a new Nitric Oxide (NO) gas delivery system. This system provides a continuous intra-breath concentration of therapeutic NO to medically supervised patients who are on ventilators in a hospital setting.

Recently, Nu-Med Plus announced it will receive its first clinical unit prototype and commence testing to verify design parameters. The design of the Nu-Med Plus clinical unit is to provide clinicians and care providers a number of key competitive advantages. The small unit fits easily into medical offices, emergency departments, as well as nursing homes. The unit offers a touch screen for ease-of-use and precision single-dose control. The clinical unit uses either a proprietary formula of nitric oxide generation or prefilled nitric oxide canisters.

Mr. Jeff Robins, Chief Executive Officer of Nu-Med Plus, stated, “The clinical unit multiplies the number of markets Nu-Med Plus is able to serve with our technology. The market-leading innovation offers providers and patients new treatment options, in new convenient environments, to address health issues that significantly impact quality of life and cost billions of dollars annually to treat.”

Nu-Med Plus, Inc. (NUMD), closed Tuesday's trading session at $0.65, up 43.7735%, on 500 volume with 1 trade. The average volume for the last 3 months is 189 and the stock's 52-week low/high is $0.449999988/$1.00.

chart

Kiwa Bio-Tech Products Group Corporation (KWBT)

Lions of Wall Street, Fast Moving Stocks, Darth Trader, Wallstreetlivechat, OTC Picks, Penny Stock Rumble, StockMister, The Penny Play, Equities, SmallCapVoice, The Stock Psycho, and Top Gun reported previously on Kiwa Bio-Tech Products Group Corporation (KWBT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Kiwa Bio-Tech Products Group Corporation is a manufacturer concentrating on eco-friendly bio-based fertilizers promoting soil health. The Company develops, manufactures, distributes, and markets novel, cost-effective and environmentally safe bio-technological products for agricultural and environmental conservation.  Organic, ecologically sound, and "green" practices are its theme. Kiwa Bio-Tech Products Group has its corporate office in Claremont, California.

Kiwa Bio-Tech’s commitment is to making safe food, further developing eco-agriculture,  and upholding a responsibility of contributing to China's agricultural safety, food safety, and a healthy lifestyle. The Company’s dedication is to eco-agricultural development and environmental control through developing, producing, and selling bio-technological products with high technology, low-cost, and high productivity to satisfy rising market demand.

The design of its products is to enhance the quality of human life through boosting the value, quality, and productivity of crops and lessening the negative environmental impact of chemicals and other wastes. The Company utilizes new bio-technological skills at its core. Its new products structure includes 16 kinds of products in 5 major categories - Biological Organic Fertilizer, Compound Microorganism Fertilizer, Microorganism Bacterium Agent, Biological Soluble Fertilizer, and Organic-Inorganic Compound Fertilizer.

Kiwa Bio-Tech launched a joint venture (JV) with Zhongshi'an Agricultural Science & Technology Co., Ltd. and Xintaitianyi Financial Service and Science & Technology Co., Ltd. The name of the JV is Inner Mongolia Jingnong Investment Management Co. Ltd. Also, Kiwa Bio-Tech has established retail outlet stores in Shaanxi Province that distribute its fertilizer products.

Recently, the Government of China is providing significant financial support and is strongly promoting the integration of farming and breeding programs in rural areas. Kiwa Bio-Tech is presently in a lead position to provide eco-friendly planting techniques and fertilizer utilization methods that will contribute to the development of the program.

Additionally, the Company anticipates enhancing local farmers’ income. Kiwa Bio-Tech received approval from the Yangling Free Trade Zone in China to obtain land for the construction of a manufacturing facility to meet the US$16 billion-dollar increasing demand for bio-fertilizers in China over the next 5 years.

Kiwa Bio-Tech Products Group Corporation (KWBT), closed Tuesday's trading session at $0.95, up 35.7143%, on 1,620 volume with 5 trades. The average volume for the last 3 months is 1,076 and the stock's 52-week low/high is $0.270999997/$1.45000004.

chart

Medibio Limited (MDBIF)

Awesome Penny Stocks, Wallet Investor, The Street, TradingView, Morningstar, Penny Stock Hub, Stockwatch, OTC Markets, Investing Online, Otc.Watch, Investors Hangout, Stockhouse, 4-Traders, and Global Banking and Finance reported earlier on Medibio Limited (MDBIF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Medibio Limited is a digital health company with offices in Melbourne (Vic), and Minneapolis, Minnesota. It has developed an objective testing system to assist in the screening, diagnosis, and treatment effectiveness of depression, chronic stress, and other mental health disorders. The test uses patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to assist in clinical diagnosis. Medibio lists on the OTC Markets’ OTCQB.

Medibio is on course to commercialize its platform technology called the Digital Mental Health Platform. The basis of this is on patented biomarkers from the autonomic nervous system. The Company’s technology will provide a Diagnosis Aid to help General Practioners (GPs) and mental health clinicians. Medibio’s technology provides the first objective measure of stress. It provides a series of user and corporate dashboards for assessment and wellness partner interventions.

Regarding biomarker based objective diagnosis, a panel of circadian, sleep, and automatic system biomarkers enables automated, repeatable, and objective characterization of the impact of mental illness on the physiologic state. Medibio’s Digital Mental Health Platform is a device agnostic platform. It can ingest data from many devices. It is highly scalable, low cost, as well as easy to integrate.

Medibio announced in October 2018 the release of ilumen™. This is its product and platform for corporate customers. ilumen™ is a corporate wellness product providing employers the ability to offer biometric analysis and objective, data-driven feedback along with a mental wellness assessment to their employees.

This past November, Medibio announced that it signed an exclusive agreement with AIAA to undertake a pilot program for the latest release of its corporate health program, ilumen™. AIAA is one of Australia’s leading life insurers. AIAA is part of the AIA Group, which is the largest independent publicly listed pan-Asian life insurance group. It has a presence in 18 markets around the Asia-Pacific region. AIAA will have access to ilumen™ over a six-month period for its Australia and New Zealand employees.

Medibio Limited (MDBIF), closed Tuesday's trading session at $0.018, up 28.5714%, on 40,000 volume with 5 trades. The average volume for the last 3 months is 34,611 and the stock's 52-week low/high is $0.0013/$0.189999997.

chart

RespireRx Pharmaceuticals, Inc. (RSPI)

NetworkNewsWire, Penny Stock Tweets, Infront Analytics, Stockflare, Barchart, InvestorsHub, Stockopedia, Penny Stock Hub, Wallet Investor, Simply Wall St, Marketbeat, YCharts, Street Insider, Marketwired, Stockhouse, Daily Marijuana Observer, last10k, Investors Hangout, GuruFocus, MarketWatch, Stockwatch, 4-Traders, and Real Investment Advice reported earlier on RespireRx Pharmaceuticals, Inc. (RSPI),  today we report on the Company, here at the QualityStocks Daily Newsletter.

RespireRx Pharmaceuticals, Inc. is a leader in the development of medicines for respiratory disorders and CNS indications, with a concentration on obstructive sleep apnea, attention deficit hyperactivity disorder (ADHD), spinal cord injury, other neurological conditions and drug-induced respiratory depression. RespireRx Pharmaceuticals has its corporate office in Glen Rock, New Jersey. The Company lists on the OTC Markets Group’s OTCQB.

RespireRx has filed over 400 patents in the U.S. and offshore that claim composition of matter, use, formulation, dosage, as well as mechanism of action. Use claims include treating sleep apnea and preventing or rescuing drug-induced respiratory depression, and also for improving memory and cognition, treating schizophrenia and other central nervous system (CNS) indications.    

  The Company’s pharmaceutical candidates in development are derived from two platforms. One platform is the class of compounds called cannabinoids. This includes, in particular, Dronabinol. Dronabinol (D9-THC, D9-tetrahydrocannabinol) is an oral capsule drug product. Dronabinol (D9-THC) is a generic, orally active cannabinoid. It is undergoing testing for clinical efficacy in patients with obstructive sleep apnea (OSA).

RespireRx Pharmaceuticals (under a license agreement with the University of Illinois) has rights to patents claiming the use of cannabinoids for the treatment of sleep-related breathing disorders. Two Phase 2 clinical trials have been completed. Both have demonstrated substantial reductions in sleep apnea produced by dronabinol. 

Dronabinol is Food and Drug Administration (FDA) approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy (Marinol®). It is a Schedule III drug available by prescription, with a low risk of addiction.

The other platform of medicines undergoing development by RespireRx is a class of proprietary compounds called ampakines. These act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptor sites in the brain. Several ampakines, in oral and injectable form, are undergoing development by RespireRx for the treatment of an assortment of breathing disorders.

Recently, RespireRx Pharmaceuticals announcd the promotion of Mr. James Sapirstein to Executive Vice Chairman of the Board of Directors effective December 28, 2018. Mr. Sapirstein has served as a member of the Board of Directors since 2014. He expands his role within RespireRx Pharmaceuticals to assist with business development and fundraising activities to advance the development of the Company’s pipeline of neuromodulators with an emphasis on sleep apnea and neurologic and psychiatric disorders.

Mr. Sapirstein is a highly-regarded pharmaceutical industry executive. He has more than 35 years of success in building companies and leading the commercial launch of almost two dozen prescription drugs in the fields of CNS, infectious disease, and cancer. Mr. Sapirstein has worked at major pharmaceutical companies, Bristol-Myers Squibb, Hoffmann-LaRoche and Eli Lilly. He has also led commercial teams for biotechnology companies including Gilead Sciences and Serono Laboratories.

RespireRx Pharmaceuticals, Inc. (RSPI), closed Tuesday's trading session at $0.67505, up 35.01%, on 503 volume with 4 trades. The average volume for the last 3 months is 323 and the stock's 52-week low/high is $0.222000002/$1.13999998.

chart

iCo Therapeutics, Inc. (ICOTF)

Amigo Bulls, Wallet Investor, Zacks, Money Hub, Street Insider, InvestorsHub, Stockhouse, Capital Cube, TheMicrocapNews, The Hot Penny Stocks, Penny Stock Tweets, OTC Markets Group, Stockwatch, TradingView, Wall St Report, Vantage Wire, MarketWatch, GuruFocus, and Clever Markets reported earlier on iCo Therapeutics, Inc. (ICOTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

iCo Therapeutics, Inc. identifies existing development stage assets for use in underserved ocular and infectious diseases. It owns the worldwide exclusive rights to an oral delivery system - Amphotericin B (Amp B) -for life-threatening infections. Amphotericin B is the gold standard for systemic antifungal drugs. It is one example of a well-established, highly efficacious systemic antifungal drug that has a 50-year history of intravenous therapy. OTCQB-listed, iCo Therapeutics is based in Vancouver, British Columbia.

The Company centers its efforts on development instead of research. iCo’s business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization, and develop them through redosing or reformulating them for new or expanded labels. iCo has its partnership with Immune Pharmaceuticals (IMNP), which is in a number of Phase 2 studies involving iCo-008. iCo-008 is also known as Bertilimumab or CAT-213.

iCo-008 is a human monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins, which acts as a messenger between the cells of the immune system. Immune Pharmaceuticals initiated a Phase 2, double-blind, placebo-controlled study with iCo-008 in 90 patients with moderate-to-severe ulcerative colitis.

iCo Therapeutics continued to advance its Oral Amphotericin B Delivery System (Oral Amp B) in 2016. Amphotericin B is a well-known approved drug for the treatment of fungal and parasitic infections. The Company is developing a proprietary oral reformulation of Amphotericin B.

This past November, iCo Therapeutics announced that it now has sufficient drug supply for a proposed mid-staged clinical trial that may be as large as 90 patients in size, investigating the efficacy and safety study of its oral Amphotericin B (oral Amp B) candidate. Moreover, based on discussions with anti-fungal experts, the Company’s intention is to conduct a comparison of oral Amp B to an approved azole drug in this proposed oral Amp B efficacy study in the area of women's health where recurrent candidiasis is common.

iCo’s licensee earlier announced a $5M USD financing for continued development of iCo-008. In addition, new clinical data has been reported in support of the drug candidate in bullous pemphigoid and pre-clinical data announced which is supportive of the potential use of iCo-008 in asthma.

iCo Therapeutics, Inc. (ICOTF), closed Tuesday's trading session at $0.0739, up 76.7943%, on 9,800 volume with 2 trades. The average volume for the last 3 months is 1,388 and the stock's 52-week low/high is $0.028999999/$0.1259.

chart

MetaStat, Inc. (MTST)

Goldman Small Cap Research, Innovative Marketing, Club Penny Stocks Network, OTCBB Journal, First Penny Picks, StocksImpossible, Pumps and Dumps, and The MicrocapNews reported previously on MetaStat, Inc. (MTST), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, MetaStat, Inc. is a personalized medicine company developing therapeutic and diagnostic treatment solutions for cancer patients. The Company develops and commercializes diagnostic products and novel therapeutics for the early and reliable prediction and treatment of systemic metastasis - the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body.  MetaStat’s focus is on breast, prostate, lung, and colorectal cancers, where systemic metastasis is responsible for approximately 90 percent of all deaths.

A life sciences company, MetaStat is headquartered in Boston, Massachusetts. In essence, MetaStat’s core expertise includes an understanding of the mechanisms and pathways that drive tumor cell invasion and metastasis, and also drug resistance to certain targeted therapies and cytotoxic chemotherapies.

  The basis of MetaStat’s function-based diagnostic platform technology is on the identification and understanding of the vital role of the mena protein and its isoforms  (a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors).

The design of the MetaSite Breast™ and MenaCalc™ product lines are to accurately stratify patients based on their individual risk of metastasis and to enable clinicians to better customize cancer treatment decisions through positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the damaging side effects and cost of chemotherapy. 

  The MetaSite Breast™ test measures the process of systemic metastasis. MenaCalc™, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is widely applicable in solid epithelial-based cancers.

The intention of the MetaSite Breast™ test is for use in patients with early stage (stage 1-3), invasive breast cancer who have node-negative or node positive (1-3), estrogen receptor-positive, HER2-negative disease.

In August of 2017, MetaStat announced that accomplished drug developer, Renato T. Skerlj, Ph.D., joined the Company as a member of its Scientific and Clinical Advisory Board. Dr. Skerlj has more than 25 years of pharmaceutical experience in drug development resulting in two marketed drugs: Invanz® and Mozobil® and numerous drugs in clinical development.

He serves as Vice President of Drug Discovery and Preclinical Development at Lysosomal Therapeutics Inc. Dr. Skerlj is a Co-Founder and a Member of the Scientific Advisory Board of X4 Pharmaceuticals, Inc. He is also Co-Founder of Noliva Therapeutics.

MetaStat, Inc. (MTST), closed Tuesday's trading session at $0.0625, up 25.00%, on 200 volume with 1 trade. The average volume for the last 3 months is 146 and the stock's 52-week low/high is $0.05/$0.163124993.

chart

Sauer Energy, Inc. (SENY)

Winston Small Cap, Shiznit Stocks, PennyStocks24, Fast Money Alerts, Penny Stock General, RockingPennyStocks, StockHideout, Investment U, DSR News, The Next Big Trade, Penny Stock Hub, BestDamnPennyStocks, and Stock Shock and Awe reported previously on Sauer Energy, Inc. (SENY), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Sauer Energy, Inc. is a technology developer and manufacturer. The Company is concentrating on the developing renewable energy market. It is the developer of the patented WindCharger™ brand vertical axis wind turbine (VAWT) and the manufacturer of the patented HelixWind® vertical axis wind turbine. Sauer Energy is uniting wind, solar, and storage together in harmony so that energy can be harnessed and processed to the greatest advantage. Sauer Energy’s head office and manufacturing facility is in Oxnard, California.

The Company is addressing worldwide energy through developing complete renewables packages by way of three energy sources that can help ensure the optimization of opportunities to capture the elements and produce electricity quicker, simultaneously, and individually. It created the WindCharger™ model to provide a better solution for the use of wind capture for residential or small building use. The WindCharger™ is one of its vital innovation priorities. Sauer Energy has several patents in place and more pending.

The design of Helix vertical axis wind turbine systems is purposely to be pole mounted and can respond to the demand for applications that do not necessitate roof mounting. Sauer’s technology requires few parts. Therefore, it provides a new direction for wind capture, scales easily from residential to small community and up to large industrial scale.

Sauer and Helix turbines underwent development to produce a quiet and low-impact technology with a high output of sustainable renewable energy. The focus of the WindCharger™ and Helix turbines has centered on patented disruptive technology, minimum impact on the environment, mounting flexibility, and versatility with highly efficient output.

The Company’s WindRider® turbine has a new mount and its own proprietary system for on-grid or off-grid structures. The Company’s intention is to offer the patented helixical WindRider® model vertical axis wind turbine that uses the HelixWind technology.

Sauer’s WindCutter turbine is a very powerful Darrieus design. The WindCutter has five airfoil blades that use the principle of lift to rotate the shaft. It is pole mounted. The Company’s WindCutter 2.5, VAWT design is the first model cleared for launch.

This past October, Sauer Energy had on view its WindCutter™ turbine solution at the Willow Springs International Motorsports Raceway, in Rosamond, California. With the installation completed and on display anyone could witness the WindCutter in operation as it produced power. The Company’s aim is to always improve technological advancements through finding new ways to make power more efficiently.

Mr. Dieter Sauer, Sauer Energy’s Chief Executive Officer and President said in late October, “What a milestone achievement for the SEI team as we enter a new chapter in our history.”

Sauer Energy, Inc. (SENY), closed Tuesday's trading session at $0.0082, up 78.2609%, on 536 volume with 00 trades. The average volume for the last 3 months is 000,000 and the stock's 52-week low/high is $0.003199999/$0.027899999.

chart

The QualityStocks Company Corner

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

With the passage of the Farm Bill, hemp will see a significant catalyst for growth. It could see even more growth once the U.S. Department of Agriculture (USDA) introduces federal hemp rules in August 2019, speeding previous plans to roll out the guidelines by 2020.  Along the way, it may just create a $39.4 billion market, says Markets and Markets, strong growth from a $10.3 billion valuation in 2018.  That’s opening a wide range of opportunity for companies, including Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI).

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Tuesday's trading session at $5.97, up 0.674536%, on 1,022,826 volume with 3,9555 trades. The average volume for the last 3 months is 1,108,191 and the stock's 52-week low/high is $2.97000002/$8.43999958.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), a manufacturer and marketer of cannabis food products, has rebranded its line of low-dosage, cannabis-infused edibles. The goal behind the new look is to ensure clarity and differentiation to its Uplift, Balance and Unwind lines for consumers (http://cnw.fm/PG53x).

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Tuesday's trading session at $2.84, off by 1.2586%, on 16,344 volume with 42 trades. The average volume for the last 3 months is 55,586 and the stock's 52-week low/high is $2.51999998/$6.00810003.

Recent News

chart

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences Inc. (CSE: WLLW)was featured in today's edition of Investorideas.com potcastsCM, http://ibn.fm/YGCXa.

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Tuesday's trading session at $0.87, up 12.99%, on 74,900 volume. The average volume for the last 3 months is 60,568 and the stock's 52-week low/high is $0.75999999/$5.25.

Recent News

chart

Sproutly Canada, Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G)

The QualityStocks Daily Newsletter would like to spotlight Sproutly Canada, Inc. (SRUTF).

Sproutly Canada (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) on Monday announced its financial results for the first quarter ended May 31, 2019. Among the updates, the company’s cash position was $3.85 million as of May 31, 2019; Toronto Herbal Remedies Inc. has received a Health Canada processing license; and the company entered into a definitive agreement with OCC Holdings Ltd., an affiliate of Moosehead Breweries Ltd, to form a joint venture. To view the full press release, visit: http://nnw.fm/R2nzz.

Sproutly Canada, Inc. (OTCQB: SRUTF) (TSX.V: SPR) (FRA: 38G) is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.

To make this happen, Sproutly acquired Infusion Biosciences to bring to market a patent-pending Aqueous Phytorecovery Process (APP) technology, a fundamental paradigm shift within the cannabis industry. Replacing traditional water-compatible solutions with true natural water solubility improves the body’s ability to utilize cannabinoids, making the effect of the cannabis almost immediate.

This revolutionary process doesn’t alter the cannabis compounds and provides an onset time and offset time that mimics the same effects as inhaled marijuana. That means consumers may feel effects in five minutes or less and be free from the desired effect in approximately 90 minutes—a vastly different ingestion pattern than current methods. In addition, the water-based cannabinoids can be mixed with other liquids and stay dissolved in those liquids. The application of water-soluble cannabis infusions has potential to be widespread in both medicinal and recreational cannabis sectors, giving Sproutly a distinctive edge in a market with untapped potential.

Sproutly’s business model is focused on processing rather than cultivating, which means its success is not constrained to growing its own cannabis. The company does own a Toronto-based, ACMPR-licensed facility designed and built with a focus on cultivating pharmaceutical-grade cannabis to produce and formulate the first natural, truly water-soluble cannabis solution. Its water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are searching for well-defined commercial products.

Sproutly’s entrance in the cannabis market is perfectly timed as cannabis is moving towards mainstream acceptance. Potential users are, however, interested in consuming cannabis products as drinks and using it as oils rather than smoking. The potential cannabis beverage market is staggering, and with Sproutly owning the exclusive rights to APP technology in Canada, Australia, Jamaica, Israel and the entire European Union, the company is looking at significant international expansion opportunities.

Sproutly plans to capitalize on these international opportunities by executing on partnerships with local and globally established consumer brands to leverage their existing customer bases, expand brand loyalty, and assist with marketing and support distribution networks to deliver scientific breakthroughs with speed and efficiency?worldwide.

Management

Sproutly believes that talent drives growth. The company is committed to bringing together the best and brightest minds in the cannabis space to help with their mission to disrupt the global beverage and consumables market.

President, CEO and Director Keith Dolo recently served for more than 13 years with Robert Half, an S&P 500, NYSE-listed company. At Robert Half, Dolo held the position of vice president for more than eight years, as well as other senior roles in both operations and sales. He also sits on an advisory committee and a board position for two nonprofits in Vancouver, BC.

Chief Science Officer and Director Dr. Arup Sent has more than 35 years of experience in research and executive management at biotechnology and pharmaceutical companies. He was awarded a PhD in biochemistry from Princeton University and is a former faculty member at the National Cancer Institute and Scripps Research Institute. Sen is the inventor on five U.S. patents and numerous international patents and patent-pending applications.

Chief Financial Officer Craig Loverock is a chartered professional accountant with over 20 years of experience in accounting and finance roles in Canada, the United States and the United Kingdom. He has extensive expertise in public company reporting and transactional experience, having served as the senior financial advisor to the chairman at Magna International and acting as chief compliance officer and CFO for a private equity firm.

Head Grower Frank Han has over 12 years of experience in the horticulture industry. A previous master grower in a large commercial facility, Han has impressive expertise in all growing methods, techniques and procedures. He brings with him a wealth of knowledge in cloning, nutrient and overall plant management. Han will be in charge of the production team at Sproutly’s Toronto Herbal Remedies facility.

Sproutly Canada, Inc. (OTCQB: SRUTF), closed Tuesday's trading session at $0.3902, up 3.3642%, on 255,532 volume with 92 trades. The average volume for the last 3 months is 448,124 and the stock's 52-week low/high is $0.189099997/$1.875.

Recent News

chart

MustGrow Biologics Corp. (CSE: MGRO)

The QualityStocks Daily Newsletter would like to spotlight MustGrow Biologics Corp..

MustGrow Biologics’ (CSE: MGRO) shares began trading on the Canadian Securities Exchange (“CSE”) on July 10, 2019 (http://nnw.fm/pPsw1). To view the full article, visit: http://nnw.fm/18J7s.

MustGrow Biologics (CSE: MGRO) is an agricultural biotech company focused on developing and commercializing its patented technology that is a natural biopesticide and biofertilizer for use as a fertilizer, nematicide, pesticide and fungicide. MustGrow’s novel and proprietary solutions utilize organic components refined from mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests such as nematodes. The company’s technology provides an all-natural, effective, safe and easy-to-use solution for farmers seeking to raise healthy crops without the use of pesticides.

Nematodes, or microscopic worms, are the most numerous multicellular animals on earth. A handful of soil will contain thousands of nematodes, many of which are parasites of insects, plants or animals. Most plant-parasitic nematodes feed on the roots of plants, damaging the root system and reducing the plant’s ability to absorb water and nutrients (http://nnw.fm/Qkz21). For the past 50 years, nematodes have been controlled using chemical nematicides, but the Environmental Protection Agency now restricts or bans many of the chemical?formulations.

MustGrow’s technologies provide nematode control that is equal and often superior to synthetic alternatives, resulting in elevated yields and increased returns for the grower. The global economic impact of soil-borne nematodes is estimated at nearly $100 billion in lost crops per year. The American Phytopathological Society (http://nnw.fm/3HGuT), an international nonprofit scientific organization dedicated to the study and control of plant diseases, estimates that plant-pathogenic nematodes are responsible for 14 percent of crop losses worldwide.

MustGrow’s technology refines mustard seeds to concentrate the plant’s natural organic compounds that form Allyl isothiocyanate (“AITC”), which serves the plant as a natural defense system against pests and diseases. As a result, MustGrow’s novel product offers first-class performance, is 100 percent natural, and its fertilizer product is listed for organic use by the Organic Materials Review Institute (“OMRI”) under specifications set by the USDA’s National Organic Program.

MustGrow’s initial technology was a granular pre-plant soil biofumigant and biofertilizer containing the active ingredient AITC, a proven nematicide, fungicide and fertilizer. The company has completed 110 independent third-party field trials on fruit and vegetable crops. As a biofertilizer, MustGrow’s product is registered with Health Canada and the EPA in all U.S. states as OMRI-certified. It is also registered for use as a biopesticide by the EPA in key fruit and vegetable growing U.S. states (except California) and with Health Canada. MustGrow is finalizing a new liquid delivery platform with increased concentration of the same active ingredient (AITC) that can be applied through drip lines to meet the demands of today’s growers.

Results of tests completed to date show that MustGrow continues to provide innovative solutions with broad based applications within agriculture. Validated field trial results include:

  • 100 percent control of root-knot nematodes in strawberry crops as compared to methyl bromide
  • 55 percent tomato crop yield increase
  • 95 percent control of Pythium root rot in lettuce fields
  • 70 percent reduction in Verticillium root severity in cucumbers
  • Market Opportunity

Market Opportunity??

MustGrow is also testing the potential application of its technology to the cannabis industry, which is projected to grow to nearly $22 billion in the U.S. by 2020. While there are no uniform guidelines for pesticide use in the cannabis industry, state-by-state regulations in the U.S. do exist which has led to instances of pesticide-tainted cannabis showing up in tested products, leading to recalls and threats of lawsuits. Health Canada recently published regulations for mandatory testing for pesticides in cannabis that are now in effect for all growers.?MustGrow’s?potential application for cannabis production shows that when its product is used as a pre-plant/pot soil treatment, it may significantly help control many soil-borne diseases, pathogens and pests, including nematodes, fusarium, rhizoctonia, and botrytis (gray mold) that affect the cannabis plant. Cannabis consumers are increasingly demanding organic products free from chemicals and have shown they are willing to pay a premium for high-quality organic cannabis. MustGrow is currently running cannabis soil trials and is seeking Health Canada approval for use of its product on cannabis.?

Global crop protection is a multibillion-dollar market that is expected to surge over the next five years. Sales of nematicides are set to grow by 33 percent to $1.43 billion by 2022, while biopesticides are projected to leap by 94 percent to an estimated?$9.5 billion by 2022. MustGrow is targeting the global nematicide industry with products that include an innovative pre-plant soil treatment. Solutions for the global biopesticide industry include seed treatment technologies, fungicides and nematicides.??

MustGrow’s groundbreaking technologies use novel plant compounds to provide superior crop protection naturally.

Management Team

President and CEO Corey Giasson is an entrepreneur with more than 20 years in the agriculture, potash, oil and gas, mining and real estate industries.? Mr. Giasson co-founded Rallyemont Energy Inc., a heavy oil company that successfully identified 140 million barrels of recoverable heavy oil, that was sold in 2013 to Husky Energy. He holds an MBA and bachelor’s degree in agricultural economics from the University of Saskatchewan.

Chairman Brad Munro has 20-plus years as a vice president/investments, with a national venture capital firm where he sourced, invested and managed the activity of over 30 companies and invested $150 million. He has served as a director of over 20 public companies and a greater number of private enterprises. Munro is currently director of Secure Energy Services.

COO Colin Betsky is the previous vice president/BioAg at Novozymes, where he was responsible for the company’s BioAg business worldwide. He holds a bachelor’s degree in agriculture from the University of Saskatchewan and has more than 20 years of experience in agricultural chemicals and biologics.

Director Tom Flow is the founder and current president of The Flowr Corporation (TSX.V: FLWR) and Licensed Producer of cannabis in Canada. He founded and built MedReleaf, Canada’s most profitable Licensed Producer which was later acquired by Aurora Cannabis?(TSX: ACB) (NYSE: ACB) for $3.2 billion. Flow is widely recognized for his leadership and expertise in building and operating cannabis cultivation facilities.

Director Matt Kowalski has a tremendous amount of experience in the fruit and vegetable and biologics industries. Under his leadership at Natural Industries, a business focused on biological pest control, the company was awarded five EPA registrations: three biofungicides, a bionematicide, and a bioinsecticide. In November 2012, Kowalski led the strategic sale of Natural Industries to Novozymes BioAg. He is the principal owner of Stronghold Keep Inc., an investment corporation.

CFO Todd Lahti has extensive experience evaluating and managing start-up companies in the biotechnology, agricultural and oil and gas sectors, working directly on financing transactions, mergers and acquisitions, corporate strategy, business development, technology transfer and operations set up. He is a Chartered Financial Analyst and a Chartered Professional Accountant.

MustGrow Biologics Corp. (CSE: MGRO), closed Tuesday's trading session at $0.35, up 11.11%, on 9,200 volume. The average volume for the last 3 months is 124,655 and the stock's 52-week low/high is $0.25/$0.699999988.

Recent News

chart

Golden Developing Solutions, Inc. (DVLP)

The QualityStocks Daily Newsletter would like to spotlight Golden Developing Solutions, Inc. (DVLP).

Golden Developing Solutions (OTC: DVLP), an emerging leader in the cannabis, hemp and cannabidiol (“CBD”) marketplace, is focused on acquiring CBD firms that are compliant with state and federal laws. An article discussing the company reads, “Fundamentally, the company focuses on two basic sectors for growth: CBD and ancillary software. To view the full article, visit: http://nnw.fm/z35QX.

Golden Developing Solutions, Inc. (DVLP), an emerging leader in ancillary software and the cannabidiol (CBD) products marketplace, provides business services and/or products supporting the cannabis industry including an online retail business for CBD, hemp oil and health/wellness related products.

Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada legalized recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. Voters in four additional U.S. states will consider marijuana initiatives on the November 2018 ballot. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.

DVLP recently acquired “Where’s Weed” (Layer Six Media LLC DBA “Where’s Weed”) and its primary asset, WheresWeed.com. Where’s Weed is an American cannabis technology company known for connecting medical and recreational cannabis users with trusted local marijuana businesses in their communities. As a rapidly growing community-based online resource for cannabis consumers with a host of user-friendly services, Where’s Weed offers a sophisticated mobile app with strong traction and powerful growth potential as the North American legal cannabis market continues to expand exponentially.

WheresWeed.com has a large and expanding reach with nearly 3 million pageviews per month. In addition, the WheresWeed mobile app, available in both iOS and Android, has been downloaded over 80,000 times, proving to be complementary to DVLP’s objective to capitalize on the massive growth curve in the marijuana space.

“The huge flood of new growers and producers is likely to create oversupply in the near term, narrowing margins for major producers,” says DVLP CEO Stavros Triant. “However, this should actually increase the net number of new consumers in the marketplace, further reinforcing the enormous growth potential for hub service providers in the space that are situated on high-traffic internet real estate, which is exactly how we view the Where’s Weed property.”

The company’s move into the lucrative C-store snack market was solidified with a material purchase order for CBD oils from a major distributor specializing in the snack foods and accessories to the convenience store and gas station market. The order represents significant progress as DVLP gears up its ready-made snack distribution strategy for its CBD products.

“We are extremely excited about the launch of our CBD product line with this distributor,” Triant states. “The C-Store strategy dovetails perfectly with our direct marketing strategy through our primary online retail channel, and we have indications from the distributor that, if this initial test order goes well, successive Purchase Orders could be significant and underpin strong sales growth in Q1 2019.”

Golden Developing Solutions, Inc. (DVLP), closed Tuesday's trading session at $0.0098, up 8.8889%, on 1,445,564 volume with 32 trades. The average volume for the last 3 months is 2,623,977 and the stock's 52-week low/high is $0.0081/$0.14.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Innovative hemp and cannabis corporation Marijuana Company of America (OTCQB: MCOA) recently signed an LOI with Alpha Private Equity & Capital and Northern Lights Distribution (“NLD”), a subsidiary of Natural Plant Extract of California (“NPE”), to form joint venture Magnolia Extracts LLC (http://nnw.fm/bz1HB). To view the full article, visit: http://nnw.fm/D7AjU.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed Tuesday's trading session at $0.0062, up 1.6393%, on 8,915,616 volume with 243 trades. The average volume for the last 3 months is 8,532,620 and the stock's 52-week low/high is $0.005985999/$0.039299998.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) this morning announced that its wholly-owned subsidiary, ABcann Medicinals Inc., has received Health Canada approval to commence extraction operations using its on-site super-critical CO2 extraction system. To view the full press release, visit: http://nnw.fm/mFX3P.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed Tuesday's trading session at $0.36, even for the day, on 117,826 volume with 61 trades. The average volume for the last 3 months is 205,574 and the stock's 52-week low/high is $0.330000013/$1.52999997.

Recent News

chart

City View Green Holdings Inc. (CSE: CVGR)

The QualityStocks Daily Newsletter would like to spotlight City View Green Holdings Inc. (CVGR).

Vertically integrated cannabis company City View Green Holdings Inc. (CSE: CVGR) is pressing forward with its efforts to establish strong operational and financial resources for its green seed-to-retail strategy, building on recent budget-strengthening developments as it completes a 40,000-square-foot cultivation facility near Toronto for a pharmaceutical-grade crop. Also today, the company was highlighted regarding the completion of the transfer of its option to purchase 49 Easton Road in Brantford to an arms-length financier who has now acquired the property.

City View Green Holdings Inc.'s (CSE: CVGR) (formerly Icon Exploration Inc.) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an A6ccess to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.

Management

Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

City View Green Holdings Inc. (CSE: CVGR), closed Tuesday's trading session at $0.125, even for the day. The average volume for the last 3 months is 121,587 and the stock's 52-week low/high is $0.094999998/$0.465000003.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences Inc. (PBIO) was featured today in a publication from NetworkNewsWire. Finding success in the lucrative yet ultra-competitive CBD industry is a daunting challenge for businesses in the space, with oversaturation in the marketplace being a real concern. The cannabis market was valued at $14.5 billion in 2018 and is projected to reach $89.1 billion by 2024, with a compound annual growth rate of 37 percent during the forecast period, according to Mordor Intelligence (http://nnw.fm/fR3cA). CBD manufacturers may find tapping into this booming trend to be short-lived if their CBD offerings don’t stand up to consumers’ expectations that the products they purchase are as beneficial as advertised.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Tuesday's trading session at $2.65, off by 7.9861%, on 8,002 volume with 30 trades. The average volume for the last 3 months is 8,726 and the stock's 52-week low/high is $1.51999998/$4.0999999.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today reported on its existing technology licensees that have entered definitive contracts to use its revolutionary DehydraTECH(TM) absorption technology within their existing and emerging brands. To view the full press release, visit: http://nnw.fm/go6Et.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $0.9849, up 1.02%, on 82,917 volume with 83 trades. The average volume for the last 3 months is 117,159 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood Holdings, Inc. (OTCQB: NGTF) was named as Virtual Investor Conferences today announced the agenda for the upcoming Virtual lnvestor Conference, the leading proprietary investor conference series.  REGISTER NOW AT:  https://tinyurl.com/Aug1VIC-AgendaPR.

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed Tuesday's trading session at $0.493, off by 3.3333%, on 130,433 volume with 61 trades. The average volume for the last 3 months is 188,885 and the stock's 52-week low/high is $0.160099998/$0.920000016.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: NABIF).

CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: A2PL) and its cutting-edge cannabis delivery system.

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: NABIF), closed Tuesday's trading session at $0.2071, off by 9.9565%, on 32,205 volume with 18 trades. The average volume for the last 3 months is 46,806 and the stock's 52-week low/high is $0.204999998/$0.791499972.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

Innovative technology holding company VPR Brands LP (OTC: VPRB) recently launched a new dry-herb vaporizer. To view the full article, visit: http://nnw.fm/zaGY2.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit?www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit?www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit?www.goldlinehemp.com?for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Tuesday's trading session at $0.043, off by 12.7789%, on 20,760 volume with 6 trades. The average volume for the last 3 months is 58,636 and the stock's 52-week low/high is $0.032099999/$0.119999997.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.